JP2023525298A5 - - Google Patents

Info

Publication number
JP2023525298A5
JP2023525298A5 JP2022567837A JP2022567837A JP2023525298A5 JP 2023525298 A5 JP2023525298 A5 JP 2023525298A5 JP 2022567837 A JP2022567837 A JP 2022567837A JP 2022567837 A JP2022567837 A JP 2022567837A JP 2023525298 A5 JP2023525298 A5 JP 2023525298A5
Authority
JP
Japan
Application number
JP2022567837A
Other languages
Japanese (ja)
Other versions
JPWO2021226576A5 (https=
JP2023525298A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/031541 external-priority patent/WO2021226576A1/en
Publication of JP2023525298A publication Critical patent/JP2023525298A/ja
Publication of JPWO2021226576A5 publication Critical patent/JPWO2021226576A5/ja
Publication of JP2023525298A5 publication Critical patent/JP2023525298A5/ja
Pending legal-status Critical Current

Links

JP2022567837A 2020-05-08 2021-05-10 Sirpアルファおよびsirpベータ1抗体、ならびにそれらの使用 Pending JP2023525298A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063022309P 2020-05-08 2020-05-08
US63/022,309 2020-05-08
PCT/US2021/031541 WO2021226576A1 (en) 2020-05-08 2021-05-10 Sirp alpha and sirp beta 1 antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2023525298A JP2023525298A (ja) 2023-06-15
JPWO2021226576A5 JPWO2021226576A5 (https=) 2024-05-20
JP2023525298A5 true JP2023525298A5 (https=) 2024-05-20

Family

ID=76197640

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022567870A Pending JP2023525753A (ja) 2020-05-08 2021-05-10 Sirpアルファ、sirpベータ1およびsirpガンマ抗体、ならびにそれらの使用
JP2022567837A Pending JP2023525298A (ja) 2020-05-08 2021-05-10 Sirpアルファおよびsirpベータ1抗体、ならびにそれらの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022567870A Pending JP2023525753A (ja) 2020-05-08 2021-05-10 Sirpアルファ、sirpベータ1およびsirpガンマ抗体、ならびにそれらの使用

Country Status (11)

Country Link
US (4) US12503508B2 (https=)
EP (2) EP4146698A1 (https=)
JP (2) JP2023525753A (https=)
KR (2) KR20230017219A (https=)
CN (2) CN115768795A (https=)
AU (2) AU2021267943A1 (https=)
CA (2) CA3177961A1 (https=)
GB (2) GB2613259A (https=)
IL (2) IL298024A (https=)
TW (2) TW202208431A (https=)
WO (2) WO2021226591A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021226591A1 (en) 2020-05-08 2021-11-11 Electra Therapeutics, Inc. Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof
CN118591619A (zh) * 2021-11-24 2024-09-03 雷格细胞股份有限公司 人诱导性调节性t细胞及其制作方法
EP4619435A1 (en) 2022-11-16 2025-09-24 Boehringer Ingelheim International GmbH Predictive efficacy biomarkers for anti-sirpa antibodies
CN117025547B (zh) * 2023-10-08 2023-12-12 迈杰转化医学研究(苏州)有限公司 产生抗b7h3单克隆抗体的杂交瘤细胞株及其应用
TW202529810A (zh) 2023-10-19 2025-08-01 美商電子療法股份有限公司 用於治療噬血球性淋巴組織細胞增生症之sirp抗體
TW202523701A (zh) 2023-10-19 2025-06-16 美商電子療法股份有限公司 用於治療癌症之sirp抗體
WO2025226691A1 (en) 2024-04-22 2025-10-30 Electra Therapeutics, Inc. Sirp alpha and beta antibodies for treatment of epstein–barr virus infections
CN119192379B (zh) * 2024-11-22 2025-01-28 四川省医学科学院·四川省人民医院 一种具有高亲和力的抗SIRPγ单克隆抗体及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015229448B2 (en) * 2014-03-11 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies
KR20260030924A (ko) * 2016-08-09 2026-03-06 키맵 리미티드 항-icos 항체
CN118027200A (zh) 2016-12-09 2024-05-14 艾利妥 抗SIRPα抗体及其使用方法
MA47111A (fr) 2016-12-22 2019-10-30 Univ Wake Forest Health Sciences Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer
JP7179743B2 (ja) * 2017-02-17 2022-11-29 オーエスイー・イミュノセラピューティクス 抗SIRPg抗体の新規の使用
CN118267470A (zh) 2017-04-13 2024-07-02 赛罗帕私人有限公司 抗SIRPα抗体
CN118271443A (zh) * 2017-05-16 2024-07-02 拜奥迪斯私人有限公司 抗SIRPα抗体
JP7395471B2 (ja) * 2017-10-13 2023-12-11 オーセ イミュノセラピューティクス 改変抗SIRPa抗体及びその使用
EP3802602A1 (en) * 2018-05-25 2021-04-14 Alector LLC Anti-sirpa antibodies and methods of use thereof
CA3140904A1 (en) 2019-06-24 2020-12-30 Amgen Inc. Inhibition of sirp-gamma for cancer treatment
US20230340112A1 (en) 2020-02-28 2023-10-26 Apexigen, Inc. Anti-sirpa antibodies and methods of use
WO2021226591A1 (en) * 2020-05-08 2021-11-11 Electra Therapeutics, Inc. Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof
WO2023086906A2 (en) 2021-11-10 2023-05-19 Electra Therapeutics, Inc. Sirp gamma antibodies and uses thereof
TW202523701A (zh) 2023-10-19 2025-06-16 美商電子療法股份有限公司 用於治療癌症之sirp抗體
TW202529810A (zh) 2023-10-19 2025-08-01 美商電子療法股份有限公司 用於治療噬血球性淋巴組織細胞增生症之sirp抗體

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016200A2 (https=)
BR102021012003A2 (https=)
BR112021013417A2 (https=)